Adrenocortical Carcinoma Treatment Market Research Report – Forecast to 2030

Adrenocortical Carcinoma Treatment Market Research Report: By Type (Localized Adrenocortical Carcinoma, Metastatic Adrenocortical Carcinoma), Therapy (Radiation Therapy and Others), End-User (Hospitals and Clinics and Others) -Forecast till 2030

ID: MRFR/Pharma/5105-HCR | February 2021 | Region: Global | 100 pages         

Adrenocortical Carcinoma Treatment Market Speak to Analyst Request a Free Sample

Adrenocortical Carcinoma Treatment Market Scenario


The adrenocortical carcinoma treatment market is expected to grow steadily over the forecast period. It is estimated that the adrenocortical carcinoma treatment market is expected to register a CAGR ~ 2.80 % with an anticipated market value of USD 832.19 million during the forecast period from 2020 to 2030.


Adrenocortical carcinoma is cancer that arises from the adrenal cortex, which is the outer layer of the adrenal gland. It is rare and aggressive in form, and the management requires a multidisciplinary approach. Numerous factors such as an increase in prevalence rates of rare cancers and the increased focus of companies on the treatment of adrenocortical carcinomas are expected to drive the growth of the market. Thus, there is an increase in the number of drugs in clinical trials for specific chemotherapeutics. According to the Journal of Clinical Endocrinology & Metabolism, the incidence of adrenocortical carcinoma ranges between 40-50 years, whereas women are 55–60% more likely to get affected with a ratio of 1.5:1. In April 2015, ArQule, Inc. announced ARQ 087 is currently in a Phase 2 trial in patients with Intrahepatic Cholangiocarcinoma (ICC) with FGFR2 fusions and a Phase 1b trial in adrenocortical tumors and tumors with FGFR translocations, amplification, and mutations. ARQ 087 is a potent FGFR (Fibroblast Growth Factor Receptor) inhibitor.


However, the discrimination of benign from malignant adrenocortical carcinoma requires the evaluation of multiple parameters. Additionally, the pathohistological diagnosis remains challenging. According to a journal published by the National Center for Biotechnology Information, the rate of incorrect initial histopathological diagnosis in Germany was 13% in the year 2016. Therefore, the lack of skilled oncology experts to derive special diagnostic algorithms remains a prominent restraint for the growth of the market. Moreover, the high risk of local recurrence and metastatic progression also hampers the growth of this market.


Segmentation


The adrenocortical carcinoma treatment market has been segmented into type, therapy, and end-user.


The market, on the basis of type, has been segmented into localized adrenocortical carcinoma and metastatic adrenocortical carcinoma.


The localized adrenocortical carcinoma segment is estimated to hold the largest share as it is the most common type with a high occurrence rate. The metastatic adrenocortical carcinoma segment is projected to be the fastest growing owing to increased occurrence rate.


The market, by therapy, has been segmented into surgery, chemotherapy, targeted therapy, radiation therapy, adjuvant therapy, and others.


The market, based on surgery, has been further segmented into laparoscopic surgery and open surgery.


The market, on the basis of radiation therapy, has been sub-segmented into external beam radiation therapy and brachytherapy.


The market, on the basis of end-user, has been segmented into hospitals and clinics, ambulatory surgical centers, and cancer research institutes.


The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The adrenocortical carcinoma treatment market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.


The European adrenocortical carcinoma treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 


The adrenocortical carcinoma treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The adrenocortical carcinoma treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.


Key players


Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO., Ltd., Hitachi, Ltd., NeuroLogica Corp., and Digirad Corporation are some of the key players in the global adrenocortical carcinoma treatment market.


Regional Market Summary


Adrenocortical Carcinoma Treatment Market Share (%), by Region, 2017


Adrenocortical Carcinoma Treatment Market Share


Source: World Health Organization (WHO), Centers for Disease Control and Prevention (CDC)


Geographically, the Americas is anticipated to dominate the adrenocortical carcinoma treatment market owing to a well-developed healthcare sector and growing healthcare expenditure. Additionally, favorable reimbursement scenario in this region contributes to the growth of the market. According to United States Surveillance Epidemiology and End Results (SEER) program, it is estimated that there are 19 to 20 new cases of adrenocortical carcinoma per year in children and adolescents in the US.


Europe is expected to hold the second largest position in the adrenocortical carcinoma treatment market. The market growth in this region owes to the availability of funds for research and increasing healthcare expenditure.


Asia-Pacific is predicted to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies. On the other hand, the Middle East & Africa is expected to have the least share of the market. Majority of the market of this region is expected to be held by the Middle East region due to growing government initiatives for the healthcare sector.


Adrenocortical Carcinoma Treatment Market, by Type



  • Localized Adrenocortical Carcinoma

  • Metastatic Adrenocortical Carcinoma


Adrenocortical Carcinoma Treatment Market, by Therapy



  • Surgery

  • Laparoscopic surgery

  • Open surgery

  • Chemotherapy

  • Targeted Therapy

  • Radiation Therapy

  • External beam radiation therapy

  • Brachytherapy

  • Adjuvant Therapy

  • Others


Adrenocortical Carcinoma Treatment Market, by End-User



  • Hospitals and Clinics

  • Ambulatory Surgical Centers

  • Cancer Research Institutes


Adrenocortical Carcinoma Treatment Market, by Region



  • Americas





    • North America

    • US

    • Canada

    • South America





  • Europe





    • Western Europe

    • Germany

    • France

    • Italy

    • Spain

    • UK

    • Rest of Western Europe

    • Eastern Europe





  • Asia-Pacific





    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific





  • Middle East & Africa





    • Middle East

    • Africa




Intended Audience



  • Pharmaceutical companies

  • Oncology research institutes

  • Research and Development (R&D) companies

  • Diagnostic laboratories

  • Government research institutes

  • Academic institutes and universities



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2023: USD 678 Million
  • 2030: 832.19 MN
  •   CAGR   2.80% (2020-2030)
      Base Year   2019
      Forecast Period   2020-2030
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Therapy, and End-user
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Arqule, Pfizer Ltd., EnGeneIC Ltd, Exelixis, Inc., Millendo Therapeutics, Inc., Merck & Co., Orphagen Pharmaceuticals, Inc., HRA Pharma, Bristol-Myers Squibb Company, General Electric Company, WG Critical Care, LLC, Mylan N.V., Fresenius Kabi AG, Sinovision Technologies (Beijing) CO. Ltd. Hitachi Ltd. NeuroLogica Corp., and Digirad Corporation
      Key Market Opportunities   New product launches and R&D Amongst major key Players
      Key Market Drivers

  • Increase in prevalence rates of rare cancers
  • Increased focus of companies on the treatment of adrenocortical carcinomas


  • Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    The CAGR for Adrenocortical Carcinoma Treatment market would be 2.80% during the forecast period.

    Lack of oncology experts and high risk of local occurrence and different metastatic progress can deter Adrenocortical Carcinoma Treatment market growth.

    The types included in Adrenocortical Carcinoma Treatment market report are localized adrenocortical carcinoma and metastatic adrenocortical carcinoma.

    The Americas would dominate the Adrenocortical Carcinoma Treatment market.

    The APAC region would dominate Adrenocortical Carcinoma Treatment market in terms of growth rate.